Medipost/Samsung Hospital joint to develop a new composite for lung disease.

Published: 2006-02-02 06:58:00

Updated: 2006-02-02 06:58:00

Medipost, a biotech company, has developed a therapeutic composite material for the treatment of lung diseases by the use of adult stem cells in association with the Dept. of Pediatrics, Seoul Samsung Hospital.

The composite materials are formulated with adult stem cells prepared from the umbi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK